CNChristabellah Namugenyi

Christabellah Namugenyi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christabellah Namugenyi has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Wellness4Students Program to Mitigate Stress, Anxiety, and Depression Among Makerere University Students in Uganda: Protocol for a Longitudinal Study

    by Stephen Ojiambo Wandera, Olivia Nankinga, Patricia Ndugga, Christabellah Namugenyi, Claire Ashaba, Noeline Nakasujja, Rosco Kasujja, Belinda Agyapong, Vincent Israel Opoku Agyapong

    Background: Research indicates that university students experience higher levels of stress, anxiety, and depression (SAD) than the general population. In Uganda, existing psychological interventions for addressing SAD among students are primarily delivered face to face, which limits effective diagnosis and treatment due to stigma, a shortage of counselors, and long waiting times, which contribute to significant unmet mental health needs. Consequently, there is an urgent need for innovative approaches to improve access to mental health services. Objective: This study aims to assess the feasibility and effectiveness of a supportive SMS text messaging program (Wellness4Students [W4S]) in reducing the prevalence of SAD among university students in Uganda. Methods: This study has a quantitative longitudinal research design. We will target 4494 undergraduate students aged 18 to 24 years who will be recruited from Makerere University, Uganda. Through advertisements on social media platforms (WhatsApp and X [formerly known as Twitter]) and websites, students will receive a link to the W4S website with information about the intervention. Eligible students will voluntarily self-subscribe to the W4S program by providing their email addresses. The subscription will be an indicator of consent required for participation in receiving the intervention. Subscribers will receive daily supportive messages for 6 months. The data will be collected from subscribers at baseline (program initiation), 1 month, 3 months (midpoint), and 6 months (program completion) through web-based surveys. Students will complete questionnaires regarding SAD and well-being. We will conduct both descriptive and inferential statistical analyses using STATA version 17. Results: The results of this study are expected within 1 year after program initiation. The data will be collected from February 2026 through October 2026. The development of the W4S app and the survey instrument has been completed. The cocreation of mental health messages with 15 undergraduate students and 2 university psychologists has been completed as of March 23, 2026. The roll-out of the program is scheduled for March 24, 2026. Conclusions: The W4S intervention is feasible. The W4S program will provide essential insight into the prevalence and correlates of SAD among Makerere University students. We will identify students who are most at risk of poor mental health outcomes.

  • Open Access

    Impact of the Timed and Targeted Counselling Model on Maternal Health Continuum of Care Outcomes in Northern Uganda: Protocol of a Quasi-Experimental Study

    by Douglas Zibugu, Jessica S. Gubbels, Christabellah Namugenyi, John Bosco Asiimwe, Sanne Gerards

    Background: About 287,000 women died globally during their pregnancy journey in 2020, yet most of these deaths could have been prevented. In Uganda, studies show that using Community Health Worker (CHW) visits to households with a pregnant woman can support the prevention of adverse maternal and neonatal outcomes. One such intervention is through the timed and targeted counselling (ttC) approach, where CHWs deliver tailored messages to mothers and their male caregivers at key stages of pregnancy. This study aims to evaluate the impact of the ttC approach on maternal health in Northern Uganda. The main outcomes include antenatal care attendance, advised place of delivery, and postnatal care visit. Methods: We will employ a cross-sectional quasi-experimental design, with retrospective data to compare an intervention group (where ttC is implemented) to a control group (without intervention) using the propensity score matching (PSM) technique applying a 1:1 ratio with a caliper width of 20% of the standard deviation to estimate the average treatment effects. Adjusted odds ratios after generating matched pairs will be reported with 95% confidence intervals with Rosenbaum sensitivity analysis carried out for robustness. Discussion: These findings can be used to modify the implementation of the ttC approach, thereby enhancing its efficiency and effectiveness.


  • Open Access

    Time to blood pressure control and predictors among patients receiving integrated treatment for hypertension and HIV based on an adapted WHO HEARTS implementation strategy at a large urban HIV clinic in Uganda

    by Willington Amutuhaire, Fred Collins Semitala, Isaac Derick Kimera, Christabellah Namugenyi, Frank Mulindwa, Rebecca Ssenyonjo, Rodgers Katwesigye, Frank Mugabe, Gerald Mutungi, Isaac Ssinabulya, et al.

    In this cohort study, we determined time to blood pressure (BP) control and its predictors among hypertensive PLHIV enrolled in integrated hypertension-HIV care based on the World Health Organization (WHO) HEARTS strategy at Mulago Immunosuppression Clinic in Uganda. From August 2019 to March 2020, we enrolled hypertensive PLHIV aged $$\ge$$ ≥ 18 years and initiated Amlodipine 5 mg mono-therapy for BP (140–159)/(90–99) mmHg or Amlodipine 5 mg/Valsartan 80 mg duo-therapy for BP ≥ 160/90 mmHg. Patients were followed with a treatment escalation plan until BP control, defined as BP < 140/90 mmHg. We used Cox proportional hazards models to identify predictors of time to BP control. Of 877 PLHIV enrolled (mean age 50.4 years, 62.1% female), 30% received mono-therapy and 70% received duo-therapy. In the monotherapy group, 66%, 88% and 96% attained BP control in the first, second and third months, respectively. For patients on duo-therapy, 56%, 83%, 88% and 90% achieved BP control in the first, second, third, and fourth months, respectively. In adjusted Cox proportional hazard analysis, higher systolic BP (aHR 0.995, 95% CI 0.989-0.999) and baseline ART tenofovir/lamivudine/efavirenz (aHR 0.764, 95% CI 0.637–0.917) were associated with longer time to BP control, while being on ART for >10 years was associated with a shorter time to BP control (aHR 1.456, 95% CI 1.126–1.883). The WHO HEARTS strategy was effective at achieving timely BP control among PLHIV. Additionally, monotherapy anti-hypertensive treatment for stage I hypertension is a viable option to achieve BP control and limit pill burden in resource limited HIV care settings.


  • Open Access

    Female's Preferred Birth Interval in Uganda: What Are The Associated Factors?

    by Douglas Candia, Edward Musoke, Christabellah Namugenyi

    Preferred birth intervals of females can have potential effects on several maternal and neonatal health outcomes. Therefore, this study aims to ascertain factors associated with preferred birth intervals among females in Uganda. The data utilized were obtained from the 2016 Uganda Demographic and Health Survey. The Pearson chi-square test and logistic regression model were used to identify independent variables significantly associated with preferred birth intervals. The results showed that the majority of females or 77.1% preferred birth intervals of at least two years. The independent factors that significantly influenced their preferences included age group, region, education level, children ever born, contraceptive use and intention, marital status, as well as current employment status. Therefore, interventions aimed at educating females about birth intervals should be tailored to the specific regions, considering their education and level of exposure to contraceptives. This knowledge will enable females to understand the information provided, which is key to making healthy choices consistent with WHO recommendations.


  • Diabetes mellitus care cascade among a cohort of persons living with HIV and hypertension in Uganda: A retrospective cohort study

    by Fortunate Ambangira, James E Sharman, Martin Muddu, Isaac Derick Kimera, Daphine Namara, Douglas Joseph Musimbaggo, Christabellah Namugenyi, Rebecca Ssenyonjo, Mary Mbuliro, Rodgers Katwesigye, et al.

    Background: In Uganda, it is recommended that persons with HIV receive integrated care to address both hypertension and diabetes. However, the extent to which appropriate diabetes care is delivered remains unknown and was the aim of this study. Methods: We conducted a retrospective study among participants receiving integrated care for HIV and hypertension for at least 1 year at a large urban HIV clinic in Mulago, Uganda to determine the diabetes care cascade. Results: Of the 1115 participants, the majority were female ( n = 697, 62.5%) with a median age of 50 years (Inter Quartile Range: 43, 56). Six hundred twenty-seven participants (56%) were screened for diabetes mellitus, 100 (16%) were diagnosed and almost all that were diagnosed ( n = 94, 94%) were initiated on treatment. Eighty-five patients (90%) were retained and all were monitored (100%) in care. Thirty-two patients (32/85, 38%) had glycaemic control. Patients on a Dolutegravir-based regimen (OR = 0.31, 95% CI = 0.22-0.46, p < 0.001) and those with a non-suppressed viral load (OR = 0.24, 95% CI = 0.07-0.83, p = 0.02) were less likely to be screened for diabetes mellitus. Conclusions: In very successful HIV care programs, large gaps still linger for the management of non-communicable diseases necessitating uniquely designed intervention by local authorities and implementing partners addressing the dual HIV and non-communicable diseases burden.


  • Open Access

    Time to blood pressure control and predictors among patients receiving integrated treatment for hypertension and HIV based on an adapted WHO HEARTS implementation strategy at a large urban HIV clinic in Uganda

    by Willington Amutuhaire, Fred Semitala, Isaac Kimera, Christabellah Namugenyi, Frank Mulindwa, Rebecca Ssenyonjo, Rodgers Katwesigye, Frank Mugabe, Gerald Mutungi, Isaac Ssinabulya, et al.

    In this cohort study, we determined time to blood pressure (BP) control and its predictors among hypertensive PLHIV enrolled in integrated hypertension-HIV care based on the World Health Organization (WHO) HEARTS strategy at Mulago Immunosuppression Clinic in Uganda. From August 2019 to March 2020, we enrolled hypertensive PLHIV aged \(\ge\)18 years and initiated Amlodipine 5mg mono-therapy for BP (140–159)/(90–99) mmHg or Amlodipine 5mg/Valsartan 80mg duo-therapy for BP ≥ 160/90mmHg. Patients were followed with a treatment escalation plan until BP control, defined as BP < 140/90 mmHg. We used Cox proportional hazards models to identify predictors of time to BP control. Of 877 PLHIV enrolled (mean age 50.4 years, 62.1% female), 30% received mono-therapy and 70% received duo-therapy. In the monotherapy group, 66%, 88% and 96% attained BP control in the first, second and third months, respectively. For patients on duo-therapy, 56%, 83%, 88% and 90% achieved BP control in the first, second, third, and fourth months, respectively. In adjusted Cox proportional hazard analysis, higher systolic BP (aHR 0.995, 95% CI 0.989–0.999) and baseline ART tenofovir/lamivudine/efavirenz (aHR 0.764, 95% CI 0.637–0.917) were associated with longer time to BP control, while being on ART for > 10 years was associated with a shorter time to BP control (aHR 1.456, 95% CI 1.126–1.883). The WHO HEARTS strategy was effective at achieving timely BP control among PLHIV. Additionally, monotherapy anti-hypertensive treatment for stage I hypertension is a viable option to achieve BP control and limit pill burden in resource limited HIV care settings.

  • Open Access

    Factors associated with blood pressure control in patients with hypertension and HIV at a large urban HIV clinic in Uganda

    by Douglas Joseph Musimbaggo, Isaac Derick Kimera, Christabellah Namugenyi, Jeremy I. Schwartz, Rebecca Ssenyonjo, Fortunate Ambangira, Lubega Kizza, Mary Mbuliro, Rodgers Katwesigye, Isaac Ssinabulya, et al.

    Globally, people living with HIV on antiretroviral therapy have an increased risk of cardiovascular disease. Hypertension is the most important preventable risk factor for cardiovascular disease and is associated with increased morbidity. We conducted an exploratory survey with hypertensive persons living with HIV who received integrated HIV and hypertension care in a large clinic in Uganda between August 2019 and March 2020 to determine factors associated with blood pressure control at six months. Controlled blood pressure was defined as n = 411, 38.7%) or obese (n = 276, 25.9%), and 98 (8.9%) had diabetes mellitus. Blood pressure control improved from 14.4% at baseline to 66.1% at 6 months. Comorbid diabetes mellitus (odds ratio (OR) = 0.41, 95% confidence interval (CI) = 0.26–0.64, p < 0.001) and HIV status disclosure (OR = 0.73, 95% CI = 0.55–0.98, p = 0.037) were associated with the absence of controlled blood pressure at 6 months. In conclusion, comorbid diabetes mellitus and the disclosure of an individual’s HIV status to a close person were associated with poor blood pressure control among persons living with HIV who had hypertension. Therefore, subpopulations of persons living with HIV with hypertension and comorbid diabetes mellitus may require more thorough assessments and intensive antihypertensive management approaches to achieve blood pressure targets.